{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:45:46Z","timestamp":1790189146650,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0193202","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T18:46:20Z","timestamp":1519238780000},"page":"e0193202","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Increased fecal calprotectin levels in Crohn\u2019s disease correlate with elevated serum Th1- and Th17-associated cytokines"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-3821","authenticated-orcid":true,"given":"Arno R.","family":"Bourgonje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius Z. H.","family":"von Martels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas Nico","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2007.11.059","article-title":"Microbial influences in inflammatory bowel diseases","volume":"134","author":"RB Sartor","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"J Cosnes","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gut.26.2.146","article-title":"Prognosis in Crohn's disease\u2014based on results from a regional patient group from the county of Copenhagen","volume":"26","author":"V Binder","year":"1985","journal-title":"Gut"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"361.e5","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases","volume":"152","author":"JF Colombel","year":"2017","journal-title":"Gastroenterology"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease","volume":"6","author":"J Jones","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings","volume":"14","author":"T Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/gutjnl-2012-303957","article-title":"Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring","volume":"62","author":"JM Benitez","year":"2013","journal-title":"Gut"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MIB.0000000000000273","article-title":"Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease","volume":"21","author":"G Boschetti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices","volume":"103","author":"J Langhorst","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/gut.47.4.506","article-title":"A simple method for assessing intestinal inflammation in Crohn's disease","volume":"47","author":"J Tibble","year":"2000","journal-title":"Gut"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/gut.2008.170019","article-title":"Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage","volume":"58","author":"D Foell","year":"2009","journal-title":"Gut"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1756283X14553384","article-title":"The role and utility of faecal markers in inflammatory bowel disease","volume":"8","author":"FS Lehmann","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-230X-12-5","article-title":"Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study","volume":"12","author":"M Manz","year":"2012","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"1285.e2","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of Inflammation in Inflammatory Bowel Disease","volume":"149","author":"BE Sands","year":"2015","journal-title":"Gastroenterology"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gut.2008.163667","article-title":"Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease","volume":"58","author":"S Brand","year":"2009","journal-title":"Gut"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"HM van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","article-title":"IBD immunopathogenesis: A comprehensive review of inflammatory molecules","volume":"16","author":"JH Park","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"MF Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"9853","key":"ref19","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"DC Baumgart","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"W O'Connor","year":"2009","journal-title":"Nat Immunol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1053\/j.gastro.2009.07.049","article-title":"Th1\/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease","volume":"137","author":"A Sakuraba","year":"2009","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/mi.2011.24","article-title":"IL-17: intestinal effector or protector?","volume":"4","author":"IJ Fuss","year":"2011","journal-title":"Mucosal Immunology"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/gut.27.7.809","article-title":"Differing acute phase responses in Crohn's disease and ulcerative colitis","volume":"27","author":"SH Saverymuttu","year":"1986","journal-title":"Gut"},{"issue":"13","key":"ref24","first-page":"90","article-title":"Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis","volume":"44","author":"C Niederau","year":"1997","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00054725-200409000-00026","article-title":"C-reactive protein as a marker for inflammatory bowel disease","volume":"10","author":"S Vermeire","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"CA Solem","year":"2005","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study","volume":"57","author":"M Henriksen","year":"2008","journal-title":"Gut"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism","volume":"37","author":"E Louis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.10.008","article-title":"Chemokine and cytokine levels in inflammatory bowel disease patients","volume":"77","author":"UP Singh","year":"2016","journal-title":"Cytokine"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4049\/jimmunol.157.3.1261","article-title":"Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5","volume":"157","author":"IJ Fuss","year":"1996","journal-title":"J Immunol"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/08916934.2015.1016221","article-title":"Selected biologic markers of inflammation and activity of Crohn's disease","volume":"48","author":"J Karczewski","year":"2015","journal-title":"Autoimmunity"},{"issue":"8292","key":"ref32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(82)90321-X","article-title":"Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis","volume":"2","author":"FC De Beer","year":"1982","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.1982.tb22136.x","article-title":"SAA, an apoprotein of HDL: its structure and function","volume":"389","author":"EP Benditt","year":"1982","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2362.1987.tb01143.x","article-title":"Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease","volume":"17","author":"RE Chambers","year":"1987","journal-title":"Eur J Clin Invest"},{"issue":"3\u20134","key":"ref35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000354689","article-title":"Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin","volume":"31","author":"T Sipponen","year":"2013","journal-title":"Dig Dis"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management","volume":"4","author":"A Dignass","year":"2010","journal-title":"J Crohns Colitis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0193202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:13:32Z","timestamp":1693548812000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0193202"}},"subtitle":[],"editor":[{"given":"John","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0193202","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,21]]}}}